{"organizations": [], "uuid": "821db96be9c52d5f95641cec7909dbe73f491893", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-janssen-collaborates-with-bristol/brief-janssen-collaborates-with-bristol-myers-squibb-to-develop-commercialize-factor-xia-inhibitors-idUSB8N1RF003", "country": "US", "domain_rank": 408, "title": "Janssen Collaborates With Bristol-Myers Squibb To Develop & Commercialize Factor XIa Inhibitors", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 1.0, "site_type": "news", "published": "2018-04-17T05:08:00.000+03:00", "replies_count": 0, "uuid": "821db96be9c52d5f95641cec7909dbe73f491893"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-janssen-collaborates-with-bristol/brief-janssen-collaborates-with-bristol-myers-squibb-to-develop-commercialize-factor-xia-inhibitors-idUSB8N1RF003", "ord_in_thread": 0, "title": "Janssen Collaborates With Bristol-Myers Squibb To Develop & Commercialize Factor XIa Inhibitors", "locations": [], "entities": {"persons": [{"name": "janssen", "sentiment": "negative"}, {"name": "laboration", "sentiment": "none"}], "locations": [{"name": "co", "sentiment": "none"}], "organizations": [{"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 16 (Reuters) - Janssen Pharmaceutical Companies:\n* JANSSEN ANNOUNCES WORLDWIDE DEVELOPMENT & COMMERCIALIZATION COLLABORATION WITH BRISTOL-MYERS TO ADVANCE THERAPY FOR CARDIOVASCULAR DISEASES\n* THE JANSSEN PHARMACEUTICAL COMPANIES - ENTERED WORLDWIDE COLLABORATION WITH BRISTOL-MYERS TO DEVELOP, COMMERCIALIZE FACTOR XIA INHIBITORS\n* JANSSEN - UNDER AGREEMENT, CO, BRISTOL-MYERS SQUIBB TO ADVANCE BMS-986177 INTO PHASE 2 CLINICAL TRIALS\n* JANSSEN - COS TO SHARE DEVELOPMENT COSTS, COMMERCIAL PROFITS AND LOSSES; ADDITIONAL TERMS OF AGREEMENT NOT DISCLOSED Source text for Eikon: Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-17T05:08:00.000+03:00", "crawled": "2018-04-17T00:20:31.000+03:00", "highlightTitle": ""}